Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Hibiscus extract has demonstrated blood-pressure-lowering effects in several clinical trials. It is generally safe. This antihypertensive action can interact with pharmaceutical antihypertensives and diuretics. It may interfere with chloroquine absorption. Avoid in pregnancy. Potential oestrogen-modulating effects warrant caution in hormone-sensitive conditions.
Biological and Chemical Classification
- Scientific Name
- Hibiscus sabdariffa
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Botanical
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for Hibiscus Flower Extract indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 26 მარ 2026, 14:13
Evidence Distribution
-
Observational / other LOW evidence YELLOWThe Chronic Elevated Consumption of Hibiscus sabdariffa Linnaeus Results in Kidney Damage Associated with Excess H(2)S. ↗Manzano-Pech L et al.. The Chronic Elevated Consumption of Hibiscus sabdariffa Linnaeus Results in Kidney Damage Associated with Excess H(2)S.. Int J Mol Sci. 2026. PMID:41828415.PMID 41828415 ↗Journal Int J Mol SciYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41828415/
-
Observational / other LOW evidence YELLOWExploring mechanisms of Hibiscus Sabdariffa in treating non-alcoholic fatty liver disease: an integrated approach utilizing network pharmacology, 3D-pharmacophore and molecular docking. ↗Nguyen CUP et al.. Exploring mechanisms of Hibiscus Sabdariffa in treating non-alcoholic fatty liver disease: an integrated approach utilizing network pharmacology, 3D-pharmacophore and molecular docking.. In Silico Pharmacol. 2026. PMID:41767854.PMID 41767854 ↗Journal In Silico PharmacolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41767854/
-
Observational / other LOW evidence YELLOWDehydrated Hibiscus sabdariffa Calyces as Anthocyanin-Rich Natural Colorants: Influence of Food-Grade Extraction and Syrup Formulation on Stability and Technological Performance. ↗Vargas MEC et al.. Dehydrated Hibiscus sabdariffa Calyces as Anthocyanin-Rich Natural Colorants: Influence of Food-Grade Extraction and Syrup Formulation on Stability and Technological Performance.. Foods. 2026. PMID:41750970.PMID 41750970 ↗Journal FoodsYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41750970/
-
Observational / other LOW evidence YELLOWEvaluation of Antioxidant Activity and Phenolic Content of Medicinal Plants Extracted by Ethanol, Methanol, and Water. ↗u00c7akmak Sancar B et al.. Evaluation of Antioxidant Activity and Phenolic Content of Medicinal Plants Extracted by Ethanol, Methanol, and Water.. J Oleo Sci. 2026. PMID:41621929.PMID 41621929 ↗Journal J Oleo SciYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41621929/
-
Observational / other LOW evidence YELLOWPreliminary formulation studies of water-soluble granules of Hibiscus sabdariffa calyx. ↗Sule Yahaya Z et al.. Preliminary formulation studies of water-soluble granules of Hibiscus sabdariffa calyx.. Pak J Pharm Sci. 2026. PMID:41620911.PMID 41620911 ↗Journal Pak J Pharm SciYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41620911/
-
Observational / other LOW evidence YELLOWHibiscus sabdariffa calyx aqueous extract mitigates alcohol withdrawal-induced anxiety and oxidative stress in mice. ↗Kouu00e9mou NE et al.. Hibiscus sabdariffa calyx aqueous extract mitigates alcohol withdrawal-induced anxiety and oxidative stress in mice.. Biochem Biophys Rep. 2026. PMID:41550511.PMID 41550511 ↗Journal Biochem Biophys RepYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41550511/
-
Observational / other LOW evidence YELLOWDeep-eutectic solvent assisted extraction of Hibiscus sabdariffa anthocyanin for the synthesis of polyvinyl alcohol/carboxy methyl cellulose composite smart films. ↗Giribabu D et al.. Deep-eutectic solvent assisted extraction of Hibiscus sabdariffa anthocyanin for the synthesis of polyvinyl alcohol/carboxy methyl cellulose composite smart films.. Int J Biol Macromol. 2026. PMID:41448314.PMID 41448314 ↗Journal Int J Biol MacromolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41448314/
-
Observational / other LOW evidence YELLOWPostbiotic metabolites present in the supernatants of Lysinibacillus xylanilyticus and Bacillus cereus promote the germination and growth of Hibiscus sabdariffa and Prosopis… ↗Ruiz-Aymu00e1 G et al.. Postbiotic metabolites present in the supernatants of Lysinibacillus xylanilyticus and Bacillus cereus promote the germination and growth of Hibiscus sabdariffa and Prosopis juliflora.. Front Microbiol. 2025. PMID:41658001.PMID 41658001 ↗Journal Front MicrobiolYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41658001/
-
Observational / other LOW evidence YELLOWEffects of Hibiscus sabdariffa calyx extract on IL-10, TNF-u03b1, and woven bone during orthodontic relapse. ↗Pakpahan EL et al.. Effects of Hibiscus sabdariffa calyx extract on IL-10, TNF-u03b1, and woven bone during orthodontic relapse.. J Taibah Univ Med Sci. 2025. PMID:41541829.PMID 41541829 ↗Journal J Taibah Univ Med SciYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41541829/
-
Observational / other LOW evidence YELLOWVegan Sesame Milk Ice Cream With Probiotic Bacteria (Lactobacillus casei) and Hibiscus (Hibiscus sabdariffa) Calyces Extract: Formulation, Characterization, and Stability. ↗Didar Z et al.. Vegan Sesame Milk Ice Cream With Probiotic Bacteria (Lactobacillus casei) and Hibiscus (Hibiscus sabdariffa) Calyces Extract: Formulation, Characterization, and Stability.. Food Sci Nutr. 2025. PMID:41458894.PMID 41458894 ↗Journal Food Sci NutrYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41458894/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Hibiscus Flower Extract. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Hibiscus Flower Extract
A score of 2.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.